arrow
A

Alessandro Marco Minisini

academic hospital of udine asufc
H指数:31
被引数:3,238
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions

高危II期皮肤黑色素瘤的辅助治疗:见解与未来方向

Cancers
IF4.4
2026-06-010
OAAI
Development of a Machine Learning Model for Predicting Treatment-Related Amenorrhea in Young Women with Breast Cancer

开发一种用于预测年轻乳腺癌女性治疗相关性闭经的机器学习模型

2025-10-290
OAAI
Post-Operative Single Fraction Stereotactic Partial Breast Irradiation (S-PBI) for Early-Stage Breast Cancer with Gammapod™ Technology: A Phase II Clinical Trial

术后单次分割立体定向部分乳腺照射(S-PBI)治疗早期乳腺癌的Gammapod™技术:一项II期临床试验

2025-10-270
PRE
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)

帕博西利尼联合来曲唑与每周紫杉醇对比,两者均联合曲妥珠单抗联合帕妥珠单抗,作为人表皮生长因子受体2阳性激素受体阳性早期乳腺癌患者的术前辅助治疗:随机II期TOUCH试验(IBCSG 55-17)的主要结果

2025-10-160
PRE
Are There High-Risk Prognostic Factors for Isolated Locoregional Recurrence in Patients With Early-Stage Breast Cancer Treated With Mastectomy Without Adjuvant Radiation Therapy?

是否存在早期乳腺癌患者在接受 mastectomy(无辅助放疗)治疗后出现孤立性局部区域复发的较高风险预后因素?

2025-10-010
OAAI
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics

激素受体阳性、HER2阴性转移性乳腺癌的纵向表型分析:基于液滴数字PCR的循环肿瘤DNA片段组学研究

2025-07-020
PRE
Differential dynamics of fragmentomic and epigenetic circulating tumor DNA (ctDNA) features in first-line Palbociclib and Ribociclib treatment for Hormone Receptor (HR) positive, HER2 negative metastatic breast cancer (MBC)
2024-05-020
PRE
Unraveling the influence of progesterone receptor status on endocrine therapy sensitivity: insight from epigenetic and fragmentomics ctDNA profiling in estrogen receptor positive, HER2 negative metastatic breast cancer (MBC)
2024-05-020
PRE
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
2024-01-020
OAAI
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study

在BRAF突变转移性黑色素瘤患者的不同预后类别中,一线靶向治疗和免疫治疗之间的比较: 一项意大利黑色素瘤组间研究

2022-08-151
OAAI
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma
2022-04-0523
OAAI